Abiraterone acetate plus low-dose prednisone demonstrated favorable results for men with metastatic castration-resistant prostate cancer progressing after docetaxel-based chemotherapy. Specifically: 1) It extended overall survival by a median of 14.8 months compared to 10.9 months for placebo and reduced the risk of death by 35%. 2) It improved time to PSA progression to 10.2 months compared to 6.6 months for placebo. 3) It produced PSA and radiographic responses and had a favorable safety profile compared to placebo with less fatigue, back pain, and spinal cord compression reported. The most common grade 3/4 adverse events for abir